Markets:

Overview

News

Currencies

International

Treasuries

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

3.755 -0.315 (-7.74%)

Streaming Delayed Price Updated: 2:17 PM EDT, Mar 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

October 02, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate ↗

October 02, 2023

SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in...

Via Benzinga

Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 29, 2023

Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.

Via Benzinga

Analyst Ratings for SAB Biotherapeutics ↗

August 21, 2023

Via Benzinga

SAB Biotherapeutics: Q1 Earnings Insights ↗

May 16, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 28, 2023

Via Benzinga

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

August 21, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 11, 2023

Via Benzinga

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

June 21, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: SAB Biotherapeutics Says Diabetes Immunotherapy Shows Therapeutic Effect In Toxicology Study ↗

June 21, 2023

SAB Biotherapeutics Inc (NASDAQ: SABS) announced the presentation of safety and pharmacologic data from a GLP toxicology study for SAB-142, a fully human immunotherapeutic being developed for delaying...

Via Benzinga

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

May 30, 2023

SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations

May 19, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results

May 16, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

May 12, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform

May 09, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 04, 2023

Via Benzinga

SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference

May 04, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials ↗

May 04, 2023

SAB Biotherapeutics Inc (NASDAQ: SABS) has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176.

Via Benzinga

SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11

May 03, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications

April 26, 2023

SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants of SARS-CoV-2

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial ↗

April 26, 2023

SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 19, 2023

Via Benzinga

Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 19, 2023

Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering.

Via Benzinga

Why Sonnet BioTherapeutics Shares Are Trading Lower By Around 13%; Here Are 20 Stocks Moving Premarket ↗

April 19, 2023

Gainers Clearmind Medicine Inc. (NASDAQ: CMND) jumped 69.3% to $0.8480 in pre-market trading after dropping 12% on Tuesday. Clearmind Medicine recently announced a $3.5 million public offering priced...

Via Benzinga

SAB Biotherapeutics Gets FDA Breakthrough Therapy Status On Influenza Treatment Candidate, Analysts Maintain Bullish Pitch ↗

April 18, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 18, 2023

Via Benzinga

Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

April 18, 2023

Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional...

Via Benzinga

Dow Dips Over 100 Points; Bank of America Earnings Beat Estimates ↗

April 18, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 100 points on Tuesday. The Dow traded down 0.42% to 33,842.93 while the NASDAQ fell 0.10% to 12,146.16. The S&P 500,...

Via Benzinga

Short Volatility Alert: Sab Biotherapeutics ↗

April 18, 2023

On Monday, shares of Sab Biotherapeutics (NASDAQ: SABS) experienced volatile short activity. After the activity, the stock price went up +6.13% to $0.77. The overall sentiment for SABS has been...

Via Benzinga

SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy

April 18, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.